Intracellular and Extracellular Lipopolysaccharide Signaling in Sepsis: Avenues for Novel Therapeutic Strategies.

Sepsis is defined as organ dysfunction due to a dysregulated systemic host response to infection. During gram-negative bacterial infection and other acute illness such as absorption from the gut infection, lipopolysaccharide (LPS) is a major mediator in sepsis. LPS is able to trigger inflammation through both intracellular and extracellular pathways. Classical interactions between LPS and host cells first involve LPS binding to LPS binding protein (LBP), a carrier. The LPS-LBP complex then binds to a receptor complex including the CD14, MD2, and toll-like receptor 4 (TLR4) proteins, initiating a signal cascade which triggers the secretion of pro-inflammatory cytokines. However, it has been established that LPS is also internalized by macrophages and endothelial cells through TLR4-independent pathways. Once internalized, LPS is able to bind to the cytosolic receptors caspases-4/5 in humans and the homologous caspase-11 in mice. Bound caspases-4/5 oligomerize and trigger the assembly of the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome followed by the activation of inflammatory caspase-1 resulting in subsequent release of interleukin-1β. Caspases-4/5 also activate the perforin gasdermin D and purinergic receptor P2X7, inducing cell lysis and pyroptosis. Pyroptosis is a notable source of inflammation and damage to the lung endothelial barrier during sepsis. Thus, inhibition of caspases-4/5/1 or downstream effectors to block intracellular LPS signaling may be a promising therapeutic approach in adjunction with neutralizing extracellular LPS for treatment of sepsis.

Introduction

Sepsis, defined as organ dysfunction due to a dysregulated host response to an infection, has a mortality rate near 40% [1]. Lipopolysaccharide (LPS) is the most common microbial mediator in sepsis and septic shock [2]. LPS is a major component of the outer membrane of gram-negative bacteria and a pathogen-associated molecular pattern which is recognized by the pattern recognition receptor toll-like receptor 4 (TLR4) [3, 4]. Once host cells recognize LPS, they release pro-inflammatory cytokines including tumor necrosis factor-α, interleukins (ILs) [5, 6]. If an imbalance occurs between pro- and anti-inflammatory mediators, the inflammatory responses are dysregulated leading to the development of sepsis. It should be noted that sepsis can also be caused by gram-positive bacterial infections and in some cases by fungi or parasites. In such cases, LPS would not play a role in pathogenesis [2].

While the relationship between extracellular LPS and TLR4 has been well documented, pharmacological interventions to neutralize circulating LPS or to block cell surface TLR4 receptors have failed in clinical trials [7]. One possible explanation for these failures is unabated LPS internalization in diverse cell types. Human lung epithelial cells, endothelial cells (ECs), cardiomyocytes, and macrophages can all internalize LPS in vitro [8, 9, 10, 11]. LPS has been shown to enter the cytoplasm of macrophages and induce inside-out pro-inflammatory signaling independent of TLR4 [11, 12, 13, 14]. Once internalized, LPS binds to the inflammatory caspases-4/5 in humans and their ortholog caspase-11 in mice, resulting in the activation of the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) and “noncanonical” inflammasomes, leading to pyroptosis, an inflammatory form of cell death. Pyroptosis of both macrophages and ECs is a contributor to inflammation and endothelium dysfunction in sepsis. Ongoing research into inhibitors of intracellular LPS signaling has shown potential in mouse sepsis models. In this review paper, we will focus discussion on how intracellular LPS is a relevant, novel therapeutic target in sepsis-associated with gram-negative bacterial infection.

Intracellular LPS Signaling

Recent studies have established the biological importance of intracellular LPS in immune response [15]. Numerous mechanisms have been proposed for LPS internalization including endocytosis of outer membrane vesicles (OMVs), endotoxin delivery protein hepatocyte-released high-mobility group (HMGB1), as well as CD14/TLR4-dependent and independent pathways [16, 17, 18]. Once inside the cytosol, LPS then acts on intracellular receptors, most notably the murine caspase-11 and the human caspases-4/5 [12, 13, 14]. Upon binding with LPS, these caspases oligomerize and activate a number of cytotoxic effectors. These include gasdermin D (GSDMD), caspase-1, and purinergic receptor P2X7. Upon effector activation, the cell begins to secrete IL-1α/β, IL-6, IL-18, and undergo pyroptosis, an inflammatory form of cell death in macrophages, ECs, and epithelial cells [9, 12, 19]. Pyroptosis of both macrophages and ECs increases levels of inflammation and causes the destruction of the lung endothelial barrier, contributing to mortality in sepsis [9, 20].

Possible Mechanisms for LPS Internalization

A number of LPS internalization pathways are suggested in the literature, including OMVs, delivery via box 1 HMGB1, and direct transport of LPS-LBP complexes. Evidence shows that OMVs produced by gram-negative bacteria can deliver LPS to the cytosol of macrophages. These vesicles interact well with cellular membranes and are transported more readily across cell membranes than free-form LPS [16]. OMVs are secreted by bacteria in a programmable fashion under stressful conditions, such as in a host environment, allowing bacteria to secrete active virulence factors which facilitates pathogenesis [21]. OMVs are internalized by host cells through endocytosis and inserted into endosomes. LPS is then released into the cytosol from these early endosomes (shown in Fig. 1a). It should be noted that Vanaja et al. [16] showed that LPS internalization can occur regardless of bacterial phagocytosis. Macrophages treated with cytochalasin D, which inhibits actin polymerization and thus phagocytosis, had equal levels of cytosolic LPS as a control [16].

Fig. 1

Overview of LPS internalization pathways. a An OMV is internalized via clathrin-mediated endocytosis. LPSs are then able to diffuse from early endosomes into the cytosol. b Hepatocytes release HMGB1 into circulation which form complexes with LPS. These HMGB1-LPS complexes are internalized via RAGE-mediated endocytosis then transported into lysosomes. HMGB1 permeabilizes lysosomal membranes, allowing LPS to access the cytosol. c Evidence suggests LPS-LBP complexes are able to enter the cytosol through unknown pathways. Diagram created with Biorender.com. LPS, lipopolysaccharide; LBP, LPS binding protein; HMGB1, he­patocyte-released high-mobility group; RAGE, receptor for advanced glycation end-products; OMV, outer membrane vesicle.

HMGB1 has also been suggested as a means of LPS internalization. In both macrophages and ECs, HMGB1 appears to bind extracellular LPS, forming HMGB1-LPS complexes which are internalized into endo-lysosomes via the receptor for advanced glycation end-products. HMGB1-LPS complexes are then delivered to acidic lysosomes. HMGB1 permeabilizes lysosome membranes, inducing release of LPS into the cytosol and subsequent caspase-11 activation (shown in Fig. 1b). It was also found that cells must be primed for this pathway with doses of extracellular LPS. Additionally, oxidized HMGB1 can interact directly with the TLR4/MD2 complex as a priming signal for subsequent NLRP3 inflammasome activation. Notably, hepatocyte-specific Hmgb1 gene deletions fail to protect mice from single high LPS doses, as demonstrated by Huebener et al. [22]. Contrastingly, Deng et al. [17] found that these deletions are protective in a double-hit endotoxemia model with an initial low, priming LPS dose, suggesting high LPS concentrations may bypass the HMGB1 pathway [22].

LPS binds to LBP in the serum, then may be internalized directly as a means of plasma clearance of LPS (shown in Fig. 1c). LPS uptake in CD14 deficient monocytes and ECs may rely on uptake of LPS-LBP complexes via scavenger receptors [23, 24]. Kopp et al. [11] demonstrated that LBP colocalizes with LPS in intracellular compartments and elicits cytokine release in TLR4 and CD14 deficient monocytes. This suggests LPS-LBP complexes can cross cell membranes independent of the CD14/TLR4 complex. Thus, LBP might function in internalizing LPS as well as being an extracellular carrier. LBP has been shown to interact with lipids and even intercalate into phospholipid bilayers, potentially allowing it to be internalized directly [11]. Holistically, more research is needed to determine which of these internalization pathways are the most significant contributors to LPS signaling or if there are other potential routes of LPS uptake.

Intracellular LPS Receptors and Effectors

Caspase-11/4/5 Bind Cytoplasmic LPS

Recent studies have described the activation of both canonical and “noncanonical” inflammasomes in response to cytoplasmic LPS, whereby LPS binds to the murine caspase-11 or the human caspases-4/5, inducing cytokine secretion and pyroptosis in macrophages [13]. When LPS is carried into the cytoplasm via cholera toxin B, murine caspase-11 is activated, resulting in subsequent pyroptosis [14, 25]. Shi et al. [12] used LPS electroporation to artificially transport LPS and found that it binds to human caspase-4, then induces inflammation and pyroptosis. Artificial transfection of LPS is not necessarily an accurate reflection of sepsis in patients. However, such studies have provided other evidence suggesting caspases are important to the LPS response. Shi et al. [12] found that knockout of the CASP4 gene with either siRNA or CRISPR/Cas9 blocked LPS-induced cytotoxicity.

Caspases-11/4/5 are structurally similar to apoptotic initiator caspases, and all contain an amino-terminal caspase activation and recruitment domain [14]. Caspase-11/4/5 bind to the lipid A moiety of LPS with the lysine residues on their caspase activation and recruitment domain domains then oligomerize (shown in Fig. 2a, b) [12, 14, 25]. Caspase-11/4/5 oligomerization is followed by the assembly of the NLRP3 inflammasome, activation of caspase-1, cleavage of GSDMD, and subsequent pyroptosis.

Fig. 2

Internal LPS signaling and pyroptosis pathways and potential therapies. a Cytoplasmic LPS binds to the CARD of procaspase-11/4/5. Pep19-2.5, an antiendotoxin peptide, can block LPS from binding to caspase-11/4/5, preventing further activation. b Activated caspase-11/4/5 begins oligomerizing and in turn activating the effectors of pyroptosis. For potential therapies, stearoyl LPC likely binds directly to caspase-11/4/5, blocking its activation and oligomerization. Azithromycin, a macrolide antibiotic, also likely interacts with caspase-11/4/5. However, its mechanism is less clear. c Caspase-11/4/5 cleaves GSDMD, generating N-terminal fragments. d N-terminal fragments of GSDMD localize to the cell membrane and oligomerize to form pores, promoting cell lysis. Necrosulfonamide directly binds to GSDMD, inhibiting its cleavage and subsequent oligomerization. e Caspase-11/4/5 cleaves C-terminal fragments of the membrane channel pannexin-1, inducing cytotoxic efflux of potassium and ATP. f Caspase-11/4/5 activates pannexin-1 and ATP efflux, which in turn activates P2X7 receptors, which begin forming pores. This results in potassium efflux, as well as sodium and calcium influx. Magnesium can inhibit the P2X7 receptor, likely by binding to extracellular ATP, which normally activates it. g Caspase-11/4/5 triggers the assembly of the NLRP3 inflammasome, which then cleaves procaspase-1 into its active form. LL-37 is an antimicrobial cathelicidin which inhibits caspase-1 activation and subsequent IL-1β se­cretion. h Caspase-1 cleaves pro-IL-1β into IL-1β. i IL-1β is secreted through membrane channels into surrounding tissue. Diagram created with Biorender.com. LPC, lysophosphatidylcholine; GSDMD, gasdermin D; LPS, lipopolysaccharide; CARD, caspase activation and recruitment domain; NLRP3, nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3.

Hagar et al. [25] and Kayagaki et al. [13] have shown that caspase-11 activation and a subsequent endotoxic shock occur in TLR4-deficient mice, following priming of TLR3 with a ligand. Evidence suggests that either TLR3 or TLR4 priming is required for upregulation of caspase-11 expression, but subsequent cytotoxic events occur independent of TLR4 [13, 25].

Caspases-11/4/5 Activate Effectors of Pyroptosis

Caspase-11/4/5 oligomers trigger the assembly of the NLRP3 inflammasome. Once assembled, the NLRP3 inflammasome cleaves procaspase-1, converting it to its active form (shown in Fig. 2g). Caspase-1 then promotes the cleavage of IL-1β, and its secretion into surrounding tissue (shown in Fig. 2h, i). Notably, NLRP3 inhibitors prevent caspase-4/5-dependent IL-1β production by intracellular LPS [26].

Caspase-11 is also able to induce pyroptosis in caspase-1 knockout mice, independent of the NLRP3 inflammasome [27]. Caspase-11/4/5 oligomers are able to act directly on GSDMD, another effector of pyroptosis. Active caspase-11/4/5 cleaves GSDMD, generating N- and C-terminal fragments. These fragments, then, are able to localize to the cell membrane, oligomerize, and form membrane pores, resulting in cell lysis (shown in Fig. 2c, d) [28].

An additional proposed mechanism by which caspase-11 elicits cell death is via pannexin-1 and purinergic receptor P2X7. Activated caspase-11 cleaves pannexin-1, a plasma membrane channel. Upon cleavage, large concentrations of ATP are released from the cell (shown in Fig. 2e). Released ATP is then able to act on the purinergic receptor P2X7, a cation channel, which then induces cytotoxic events including pore formation in the plasma membrane, potassium efflux, as well as sodium and calcium influx (shown in Fig. 2f). Extracellular LPS priming accentuates this pathway as it induces expression of caspase-11. It should also be noted that intracellular LPS appears to directly heighten the sensitivity of the P2X7 receptor to ATP release [29, 30].

In summary, caspases-11/4/5 is able to induce the ­secretion of IL-1β via NLRP3 and caspase-1 activation, while also inducing cell lysis via both the perforin GSDMD and cation channel P2X7. It should also be noted that priming of cells by extracellular LPS upregulates expression of caspase-11/4/5, increasing activation and heightening the downstream effects of intracellular LPS pathways [14, 29].

Implications of LPS Internalization in Sepsis

Pyroptosis Increases Inflammation

Pyroptosis of immune cells combats intracellular infection [31]. In vivo, this promotes clearance of intracellular pathogens as bacteria are released by pyroptosis into the extracellular space then phagocytosed by nearby macrophages or neutrophils [32].

During sepsis, as endotoxins enter the cytoplasm of macrophages, the cells undergo pyroptosis and increase local inflammation [27, 33, 34]. Studies have shown that caspase-1- and NLRP3-deficient mice undergo less macrophage pyroptosis, produce less IL-1β, and are more resistant to LPS-induced septic shock [35, 36, 37]. Additionally, Wang et al. [20] demonstrated that inflammation was correlated with pyroptotic mononuclear cells in a prospective study of 60 trauma patients. They found a significant correlation between mononuclear cell pyroptosis and clinical measures including injury severity score, chronic health evaluation II score, and cytokine (IL-10, IL-18, and MCP-1) levels [20].

Pyroptosis in the Endothelium Leads to Acute Lung Injury

Sepsis often leads to destruction of the lung endothelial barrier, resulting in edema, hypoxemia, and death [38]. Damage to the lung endothelial barrier can be caused by caspase-11/4/5-mediated pyroptosis [9, 39, 40]. During sepsis, the death of ECs coincides with microtubule activation, actin cytoskeleton remodeling, and disassembly of endothelial adherens junctions. This endothelium dysfunction leads to cell retraction, gap formation, and subsequent edema. In vitro experiments have shown that intracellular LPS induces far greater cytotoxicity in ECs when than extracellular LPS [9, 41]. However, priming of ECs by extracellular LPS upregulates caspases-4/5 [9]. ECs in the absence of priming can also undergo pyroptosis but required more prolonged exposure to intracellular LPS [9].

Destruction of the endothelial barrier results in protein-rich edema, activation of procoagulant pathways, release of pro-inflammatory cytokines, and influx of leukocytes. Deletion of caspase-11 in mice showed reduced endothelial permeability and enhanced survival upon LPS challenge [9]. Caspase-1 knockout mice also show a reduction of nearly 70% in EC death following sepsis [42]. This widespread lysis of ECs leads to acute lung injury in sepsis. Other than LPS internalization, Mitra et al. [43, 44] suggested that EC pyroptosis during sepsis is stimulated by the transport of microparticles containing activated caspase-1 and GSDMD from monocytes to ECs.

Pyroptosis and Acute Kidney Injury

It has also been reported that caspase-11-mediated pyroptosis occurs in renal tubular epithelial cells and may be a cause for acute kidney injury, another complication of sepsis [19, 45]. Ye et al. [19] examined acute kidney injury in a mouse model with caspase-11 knockout strains, along with accompanying in vitro work. The authors found that LPS injection resulted in lytic death of renal tubular epithelial cells, along with increased expression of caspase-11 and GSDMD in wild type strains. Caspase-11 knockout strains showed reduced abnormalities in renal structure and serum creatinine levels, indicating improved renal function [19]. Studies have found that oxidative stress and mitochondrial dysfunction also play a role in septic acute kidney injury [46, 47]. Li et al. [47] found that heme oxygenase protects mice against these damaging processes. Antioxidant compounds may also protect against these pathways. There is still a need for further research into pyroptosis in its induction of septic acute kidney injury, in order to find additional therapeutic targets. The effects of pyroptosis are summarized in Table 1.

Table 1

Summary of effects of pyroptosis in sepsis

Effect of pyroptosis	Model	Citation
Increases local inflammation, IL-1β and IL-18 production, induces macrophage cell death	Murine model with a intraperitoneal LPS single dose of	Kayagaki et al. [13]
Induces EC death, destruction of the lung endothelial barrier and subsequent pulmonary edema, acute lung injury	Murine model with a intraperitoneal LPS single dose of	Cheng et al. [9]
Lytic death of renal tubular epithelial cells, abnormalities in renal structure, acute kidney injury	Murine model with a intraperitoneal LPS single dose of	Ye et al. [19]

IL, interleukin; LPS, lipopolysaccharide; EC, endothelial cell.

Past Therapeutic Efforts

LPS Neutralization Clinical Trials

Monoclonal antibodies have been suggested for use in neutralizing circulating LPS and, thus, preventing its interaction with extracellular and intracellular receptors. However, antibody use has not been supported by clinical trials [7]. One tested antibody, HA-1A, proved to be ineffective in reducing a 14-day mortality in patients with sepsis or gram-negative endotoxemia [48]. HA-1A may have been affected by limited specific endotoxin-binding ability [49]. Ineffectiveness of LPS antibodies has been attributed to a number of factors including extreme sensitivity of humans to endotoxin when compared to animals and differences between preclinical and clinical experience [50].

Other forms of LPS antibodies may show more promise. These include antimicrobial peptides, short amino acid chains normally secreted by innate immune systems [51]. A recombinant N-terminal fragment of bactericidal/permeability-increasing protein (21) also known as Opebacan has shown efficacy in neutralizing LPS in vitro and murine models, following intravenous LPS infusion [52]. This drug has also shown efficacy in specific patient subgroups, such as in children with severe meningococcal sepsis [53].

TLR4 and CD14 Antagonist Clinical Trials

TLR4 antagonists have been largely unsuccessful as therapeutic agents in the treatment of sepsis. Eritoran seemed promising as a therapeutic treatment for sepsis during phase I and II clinical trials [54, 55]. However, during phase III clinical trials, Eritoran was unable to significantly reduce mortality in patients with severe sepsis when compared to placebo [56].

TAK-242 is another small molecule developed to inhibit TLR4 signal transduction [57]. Evaluation of TAK-242 in a murine model of endotoxin shock showed protection for mice from LPS-induced mortality [58]. During phase III clinical trials, the drug failed to reduce cytokine levels or decrease mortality rates in sepsis patients [59].

Monoclonal antibodies which antagonize CD14 have also been tested as therapy for sepsis. This includes IC14, a recombinant chimeric monoclonal antibody which binds to both membrane-bound and soluble forms of CD14. IC14 was well tolerated in a phase I clinical trial in sepsis patients [60]. Other anti-CD14 antibodies continue to be explored as a means of treatment [61].

Novel Therapeutic Strategies

Caspase-11 Inhibitors

To our knowledge, there have been no clinical trials with caspase inhibition therapy in sepsis patients. However, there have been promising results in mouse studies [62]. Li et al. [63] demonstrated that stearoyl lysophosphatidylcholine shows protective effects in vivo against sepsis in a mouse model using intraperitoneal injection of LPS. Lysophosphatidylcholine is a component of lipoproteins and appears to competitively inhibit caspase-11 activation, GSDMD cleavage, and IL-1β release (shown in Fig. 2b). Additionally, azithromycin, a macrolide antibiotic, has been shown to inhibit LPS-induced IL-1β release in an LPS injection mouse sepsis model, by impairing caspase-11 activation (shown in Fig. 2b) [64]. Furthermore, Pep19-2.5 is an antiendotoxin peptide which protects against a sepsis model of endotoxemia in vivo and is able to impair caspase-11 activation, IL-1β release, and pyroptotic cell death in human monocytes and macrophages in vitro (shown in Fig. 2a) [65].

Other Caspase Inhibitors

Caspase-1 and broad caspase inhibitors have also shown success in mouse models. LL-37, a human cathelicidin (antimicrobial peptide) is able to neutralize the action of intracellular LPS and inhibit pyroptosis, improving sepsis survival in mice. Its mechanisms of action include direct LPS binding and neutralization, as well as impairment of caspase-1 activation (shown in Fig. 2g) [66].

Studies have shown that broad caspase inhibitors can prevent lymphocyte apoptosis in cecal ligation and puncture murine models and improve survival outcomes [67, 68]. Weber et al. [68] administered VX-166, a broad caspase inhibitor which targets both apoptotic and inflammatory caspases, arresting lymphocyte apoptosis. Caspase-1 has shown involvement in both monocyte pyroptosis and lymphocyte apoptosis [36]. Thus, blocking caspase-1 could slow both of these pathological mechanisms. Another study using a broad caspase inhibitor found that it prevented endotoxemia-induced cardiac dysfunction in rats [69].

GSDMD Inhibitors

GSDMD may be inhibited by necrosulfonamide, a compound which prevents assembly of GSDMD oligomers and subsequent pore formation and pyroptotic death. This drug is able to improve survival from sepsis in mice following LPS administration (shown in Fig. 2d) [70]. Magnesium also appears to inhibit pyroptosis and GSDMD activation via inhibiting channel P2X7, preventing calcium influx into the cell upon LPS internalization (shown in Fig. 2f). As mentioned earlier, calcium influx is a contributor to pyroptotic cytotoxicity. Calcium influx also seems to be required for GSDMD pore formation [71].

Future Efforts

Sepsis is a complex condition, requiring evolving strategies. TLR4 blocking and neutralization of circulating LPS seem like promising strategies, yet they have been largely unsuccessful [48, 72]. Intracellular LPS signaling has certainly been neglected in the previous clinical trials as an important contributor to mortality in sepsis. Adjunctive therapy could simultaneously target both TLR4-independent and TLR4-dependent LPS signaling pathways through a multipronged strategy including neutralization of LPS in circulation, blocking of TLR4 receptors, and blocking of internal LPS receptors. Intracellular LPS pathways have a number of targets including the inflammatory caspases-4/5/1 as well as their effectors, GSDMD, and the P2X7 receptor.

Current forms of sepsis treatment could show increased effectiveness when used adjunctively with internal LPS receptor antagonists. Similarly, previous forms of treatment which lacked efficacy, such as TLR4 blockers, may show added benefits as cointerventions with this new line of therapies.

There are numerous concerns involved with caspase therapy. Broad caspase inhibitors in large doses can have side effects including cytotoxicity. Caspases have also been shown to have other nonapoptotic functions, such as immune regulation. For example, caspase-1 also protects against colorectal tumorigenesis through secretion of IL-18, which appears to activate tumor suppressors such as IFN-γ [73]. Disturbing these protective effects may produce adverse events in patients [74]. Finally, studies have shown that apoptosis can be initiated by only small amounts of activated caspase-3, meaning therapies might require a high degree of inhibition [75]. Selective caspases-4/5/1 inhibition could avoid some pitfalls of broad caspase inhibition. Ac-YVAD-cmk is a cell-permeable inhibitor of only the inflammatory caspases-1/4/5. An in vitro or animal study using Ac-YVAD-cmk could show promising results, given the documented roles of these caspases in sepsis [76].

Conclusions

Sepsis associated with gram-negative bacterial infection is affected through both extracellular and intracellular signaling. Intracellular LPS is able to bind to caspase-11 in mice cells and caspase-4/5 in human cells, eliciting inflammation and pyroptotic cell death. A number of pathways for LPS internalization, including outer-membrane vesicles and delivery via HMGB1, have been discussed in the literature. Inside-out LPS signaling may explain the failure of LPS neutralization and TLR4 blockage in clinical trials due to the ongoing inflammatory effects of cytoplasmic LPS. In humans, intracellular signaling could be antagonized through targeting the inflammatory caspases-4/5/1 or their cellular effectors, including GSDMD and the P2X7 receptor. Conjunction therapy with LPS neutralization, TLR4 blocking, and inhibition of the human inflammatory caspases-4/5/1 presents an intriguing therapeutic option, which could be investigated in vivo. Ultimately, the evidence from animal models warrants clinical investigation into targeting of intracellular LPS in sepsis.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

The study was supported by the Canadian Institutes of Health Research FDN143285 to Dr. Haibo Zhang and the National Nature Science Foundation of China 81270125 to Dr. Yimin Li.

Author Contributions

R.G. contributed to research and drafting of the manuscript. M.L. contributed to creation of the study outline, review of the literature, and drafting of the manuscript. P.Z. contributed to research and drafting of the manuscript. J.M. and Y.L. contributed to revision and editing of the manuscript. H.Z. contributed to design of the review outline, revision, editing, and writing of the manuscript.